The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial release generated substantial returns, the expiration of its patent opened the door to off-brand https://mirrorbookmarks.com/story21547997/sildenafil-and-the-pharmaceutical-industry-a-precarious-investment